ProKidney’s Rilparencel Delivers 78% eGFR Gain as FDA Backs Surrogate Endpoint

Introduction

ProKidney Corp. (NASDAQ: PROK) is a late clinical-stage biotechnology company headquartered in Winston-Salem, North Carolina. The company is developing an autologous cell therapy candidate, rilparencel (REACT®), aimed at preserving kidney function in patients with advanced chronic kidney disease (CKD) who have limited therapeutic options beyond dialysis.

Corporate Structure

Founded in 2015, ProKidney employs between 51 and 200 professionals across clinical operations, research and development, manufacturing, and corporate functions. Its leadership team includes experts in regenerative medicine, nephrology, and cell therapy manufacturing. The company has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for rilparencel.

Kidney therapy by Robina Weermeijer

Developments and News

• Phase 2 REGEN-007 Results (July 8, 2025): ProKidney announced a 78% improvement in estimated glomerular filtration rate (eGFR) slope in Group 1 (n=24) following treatment with rilparencel. Full data will be submitted to the American Society of Nephrology’s Kidney Week in November 2025.
• FDA Alignment (July 2025): At a Type B meeting, the FDA confirmed that eGFR slope from the ongoing Phase 3 PROACT 1 study may serve as a surrogate endpoint for accelerated approval and support a Biologics License Application.
• Enrollment Update (August 12, 2025): More than half of the patients required for the accelerated approval analysis have been enrolled in the PROACT 1 study, with topline data anticipated in Q2 2027.
• Quarterly Financial Results (June 30, 2025): ProKidney ended Q2 2025 with $295 million in cash, cash equivalents, and marketable securities, which are projected to sustain the company’s operations into mid-2027.
• Ownership Disclosure (August 7, 2025): Morgan Stanley Investment Management disclosed holdings of 5,712,128 shares, representing 4.4% of outstanding shares, but indicated that it has ceased to be a beneficial owner above the 5% threshold.
• Conferences (August 27, 2025): ProKidney will present at the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference.
• Manufacturing Expansion (2027): ProKidney is set to establish a new manufacturing facility in Greensboro, North Carolina, with the potential to create approximately 330 life sciences jobs. This project is supported by a 12-year Job Development Investment Grant.

Financial and Strategic Analysis

ProKidney’s liquidity position of $295 million as of June 30, 2025, provides a foundation for ongoing investment in its Phase 3 program and associated operations through mid-2027. The FDA’s acceptance of eGFR slope as a surrogate endpoint offers a clearer regulatory pathway, potentially leading to expedited approval for rilparencel. The Greensboro manufacturing site aims to enhance the company’s capacity for patient-specific cell therapies, aligning with state incentives and advancing commercial readiness upon regulatory approval. Engagement in major healthcare conferences and collaborations with academic institutions may help maintain visibility among clinicians and investors.

Market Position and Industry Context

Over 35 million U.S. adults are diagnosed with CKD, with approximately 135,000 patients progressing to dialysis annually. Therapeutic options for patients with Stage 4 CKD are limited; existing treatments can slow disease progression in some cases, but many patients advance to end-stage renal disease. Rilparencel, as an autologous cell therapy, represents one of the few late-stage approaches targeting the preservation of kidney function in diabetic patients at high risk of renal failure, positioning ProKidney within a specialized segment of the biotechnology industry focused on addressing unmet medical needs.

TL;DR

On July 8, 2025, ProKidney’s Phase 2 REGEN-007 trial demonstrated a 78% improvement in eGFR slope. In July 2025, the FDA confirmed that eGFR slope from the Phase 3 PROACT 1 study can serve as an accelerated approval endpoint, with topline data expected in Q2 2027. As of June 30, 2025, the company reported $295 million in liquidity. A manufacturing facility in Greensboro, NC, is expected to create approximately 330 jobs by 2027, supported by a 12-year grant. ProKidney is scheduled to present at the Citi Biopharma Back to School and Morgan Stanley Global Healthcare conferences on August 27, 2025.